Clinical trial
Randomized, Double-Blind Parallel-Group, Adaptive, Three-Arm, Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing Bronchopulmonary Dysplasia (BPD) in High-Risk Preterm Neonates Compared to Standard of Care (SOC)
NCT06897839 is registered in ClinicalTrials.gov with Airway Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Double-Blind Parallel-Group, Adaptive, Three-Arm, Phase 2b/3 Multicenter Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing Bronchopulmonary Dysplasia (BPD) in High-Risk Preterm Neonates Compared to Standard of Care (SOC)
- Lead sponsor
- Airway Therapeutics, Inc.
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- February 3, 2025
- Completion date
- April 30, 2030
- Enrollment
- 366 (estimated)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.